Research programme: MRI contrast agents - Bayer HealthCare Pharmaceuticals
Alternative Names: gadofluorine derivatives; gadofluorine-M; gadofluorine-PLatest Information Update: 04 Nov 2017
At a glance
- Originator Bayer Schering Pharma; EPIX Pharmaceuticals
- Developer Bayer HealthCare Pharmaceuticals
- Class Contrast media; Lanthanoid series elements; Organometallic compounds
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer metastases; Vascular disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer-metastases(Diagnosis) in Germany (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Vascular-disorders(Diagnosis) in Germany (Parenteral)
- 20 Apr 2010 Preclinical trials in Cancer metastases in Germany (Parenteral)